Cargando…

Five-Year Outcomes of Post-Drug-Coated Balloon Angioplasty Dissection in Complex Femoropopliteal Artery Disease

OBJECTIVE: To evaluate the long-term outcomes after drug-coated balloon (DCB) angioplasty dissection in patients with complex femoropopliteal artery disease. METHODS: Two hundred patients with femoropopliteal peripheral artery disease were enrolled in the AcoArt I trial and randomly assigned to eith...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Hao, Liu, Jie, Zhang, Jiwei, Zhuang, Baixi, Fu, Weiguo, Wu, Danming, Wang, Feng, Zhao, Yu, Guo, Pingfan, Bi, Wei, Wang, Shenming, Guo, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352644/
https://www.ncbi.nlm.nih.gov/pubmed/34385840
http://dx.doi.org/10.2147/IJGM.S316916
_version_ 1783736227397107712
author Ren, Hao
Liu, Jie
Zhang, Jiwei
Zhuang, Baixi
Fu, Weiguo
Wu, Danming
Wang, Feng
Zhao, Yu
Guo, Pingfan
Bi, Wei
Wang, Shenming
Guo, Wei
author_facet Ren, Hao
Liu, Jie
Zhang, Jiwei
Zhuang, Baixi
Fu, Weiguo
Wu, Danming
Wang, Feng
Zhao, Yu
Guo, Pingfan
Bi, Wei
Wang, Shenming
Guo, Wei
author_sort Ren, Hao
collection PubMed
description OBJECTIVE: To evaluate the long-term outcomes after drug-coated balloon (DCB) angioplasty dissection in patients with complex femoropopliteal artery disease. METHODS: Two hundred patients with femoropopliteal peripheral artery disease were enrolled in the AcoArt I trial and randomly assigned to either the DCB or percutaneous transluminal angioplasty (PTA) group. A total of 86 patients with post-balloon angioplasty dissection were reanalyzed. The primary endpoint was clinically driven target lesion revascularization (CD-TLR) over five years. Kaplan–Meier curve estimates were used to evaluate the association between the treatment and CD-TLR. Interaction and stratified analyses were also performed. RESULTS: Over five years, patients treated with DCB angioplasty demonstrated an acceptable effect with a numerically higher but not statistically significant rate of freedom from CD-TLR compared with those treated by PTA (Kaplan–Meier estimate of 77.6% vs 64.4%; log-rank P = 0.08). Among the patients who underwent TLR, the mean time from intervention to TLR in the DCB group was significantly prolonged compared to the PTA group (P < 0.001). The stratified analysis showed that the Rutherford classification played an interactive role in the association between the DCB angioplasty and low CD-TLR rate at five years. No significant difference in the all-cause mortality was found in the patients with post-balloon angioplasty dissection between the two treatment groups. CONCLUSION: The five-year follow-up outcomes of the post-balloon angioplasty dissection in the AcoArt I trial demonstrated that DCB angioplasty is more trustworthy than PTA, with a higher rate of freedom than CD-TLR and sustained improvement in clinical symptoms. However, the all-cause mortality rate in patients with femoropopliteal lesions is similar after both DCB angioplasty and PTA. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov. UNIQUE IDENTIFIER: NCT01850056.
format Online
Article
Text
id pubmed-8352644
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-83526442021-08-11 Five-Year Outcomes of Post-Drug-Coated Balloon Angioplasty Dissection in Complex Femoropopliteal Artery Disease Ren, Hao Liu, Jie Zhang, Jiwei Zhuang, Baixi Fu, Weiguo Wu, Danming Wang, Feng Zhao, Yu Guo, Pingfan Bi, Wei Wang, Shenming Guo, Wei Int J Gen Med Clinical Trial Report OBJECTIVE: To evaluate the long-term outcomes after drug-coated balloon (DCB) angioplasty dissection in patients with complex femoropopliteal artery disease. METHODS: Two hundred patients with femoropopliteal peripheral artery disease were enrolled in the AcoArt I trial and randomly assigned to either the DCB or percutaneous transluminal angioplasty (PTA) group. A total of 86 patients with post-balloon angioplasty dissection were reanalyzed. The primary endpoint was clinically driven target lesion revascularization (CD-TLR) over five years. Kaplan–Meier curve estimates were used to evaluate the association between the treatment and CD-TLR. Interaction and stratified analyses were also performed. RESULTS: Over five years, patients treated with DCB angioplasty demonstrated an acceptable effect with a numerically higher but not statistically significant rate of freedom from CD-TLR compared with those treated by PTA (Kaplan–Meier estimate of 77.6% vs 64.4%; log-rank P = 0.08). Among the patients who underwent TLR, the mean time from intervention to TLR in the DCB group was significantly prolonged compared to the PTA group (P < 0.001). The stratified analysis showed that the Rutherford classification played an interactive role in the association between the DCB angioplasty and low CD-TLR rate at five years. No significant difference in the all-cause mortality was found in the patients with post-balloon angioplasty dissection between the two treatment groups. CONCLUSION: The five-year follow-up outcomes of the post-balloon angioplasty dissection in the AcoArt I trial demonstrated that DCB angioplasty is more trustworthy than PTA, with a higher rate of freedom than CD-TLR and sustained improvement in clinical symptoms. However, the all-cause mortality rate in patients with femoropopliteal lesions is similar after both DCB angioplasty and PTA. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov. UNIQUE IDENTIFIER: NCT01850056. Dove 2021-08-05 /pmc/articles/PMC8352644/ /pubmed/34385840 http://dx.doi.org/10.2147/IJGM.S316916 Text en © 2021 Ren et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Clinical Trial Report
Ren, Hao
Liu, Jie
Zhang, Jiwei
Zhuang, Baixi
Fu, Weiguo
Wu, Danming
Wang, Feng
Zhao, Yu
Guo, Pingfan
Bi, Wei
Wang, Shenming
Guo, Wei
Five-Year Outcomes of Post-Drug-Coated Balloon Angioplasty Dissection in Complex Femoropopliteal Artery Disease
title Five-Year Outcomes of Post-Drug-Coated Balloon Angioplasty Dissection in Complex Femoropopliteal Artery Disease
title_full Five-Year Outcomes of Post-Drug-Coated Balloon Angioplasty Dissection in Complex Femoropopliteal Artery Disease
title_fullStr Five-Year Outcomes of Post-Drug-Coated Balloon Angioplasty Dissection in Complex Femoropopliteal Artery Disease
title_full_unstemmed Five-Year Outcomes of Post-Drug-Coated Balloon Angioplasty Dissection in Complex Femoropopliteal Artery Disease
title_short Five-Year Outcomes of Post-Drug-Coated Balloon Angioplasty Dissection in Complex Femoropopliteal Artery Disease
title_sort five-year outcomes of post-drug-coated balloon angioplasty dissection in complex femoropopliteal artery disease
topic Clinical Trial Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352644/
https://www.ncbi.nlm.nih.gov/pubmed/34385840
http://dx.doi.org/10.2147/IJGM.S316916
work_keys_str_mv AT renhao fiveyearoutcomesofpostdrugcoatedballoonangioplastydissectionincomplexfemoropoplitealarterydisease
AT liujie fiveyearoutcomesofpostdrugcoatedballoonangioplastydissectionincomplexfemoropoplitealarterydisease
AT zhangjiwei fiveyearoutcomesofpostdrugcoatedballoonangioplastydissectionincomplexfemoropoplitealarterydisease
AT zhuangbaixi fiveyearoutcomesofpostdrugcoatedballoonangioplastydissectionincomplexfemoropoplitealarterydisease
AT fuweiguo fiveyearoutcomesofpostdrugcoatedballoonangioplastydissectionincomplexfemoropoplitealarterydisease
AT wudanming fiveyearoutcomesofpostdrugcoatedballoonangioplastydissectionincomplexfemoropoplitealarterydisease
AT wangfeng fiveyearoutcomesofpostdrugcoatedballoonangioplastydissectionincomplexfemoropoplitealarterydisease
AT zhaoyu fiveyearoutcomesofpostdrugcoatedballoonangioplastydissectionincomplexfemoropoplitealarterydisease
AT guopingfan fiveyearoutcomesofpostdrugcoatedballoonangioplastydissectionincomplexfemoropoplitealarterydisease
AT biwei fiveyearoutcomesofpostdrugcoatedballoonangioplastydissectionincomplexfemoropoplitealarterydisease
AT wangshenming fiveyearoutcomesofpostdrugcoatedballoonangioplastydissectionincomplexfemoropoplitealarterydisease
AT guowei fiveyearoutcomesofpostdrugcoatedballoonangioplastydissectionincomplexfemoropoplitealarterydisease